Latest News

STAT Plus: Pharmalittle: A biotech incubator bought a brokerage to tout its firms; FDA failed to thwart risky fentanyl prescribing

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest. We will take in another installment of our “Let’s-see-them-before-they-die” concert series, hang with a couple of our short people, manicure the official grounds, and take a nap or three. And what about you? This is the high season for summer getaways — will you be out and about, or planning to do so? You could also take advantage of the slightly slower pace and catch up on your reading. Or you could calculate how much the tariff wars will cost you. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Over the past year, National Securities analyst Jonathan Aschoff issued bullish notes on three biotechs, but did not mention his employer is owned by the same company, Fortress Biotech (FBIO), that controls each biotech, Reuters reports. Fortress is the brainchild of longtime biotech entrepreneurs Dr. Lindsay Rosenwald and Michael Weiss. Owning National gives Fortress an in-house underwriter and private sales force of about 700 brokers, nearly a third of whom have been flagged by regulators, to help it raise money for its stable of nine ventures that are developing new drugs.

Continue to STAT Plus to read the full story…

Source link

Related posts

Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens


Medical News Today: Is it safe to use marijuana while breastfeeding?


Reminder: Medgadget 2018 Sci-Fi Writing Contest: Win The Eko Digital Stethoscope


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy